Initially developed as glucose-lowering agents for treating type 2 diabetes mellitus (T2DM), SGLT2 inhibitors have demonstrated a broad spectrum of benefits beyond glycemic control. Here, SLC5A2 is linked to type 2 diabetes mellitus.